All In Biotech

Drug Trial Radar · NCT03363321

PF-06741086 Long-term Treatment in Severe Hemophilia

A MULTICENTER, OPEN-LABEL STUDY TO EVALUATE THE LONG-TERM SAFETY, TOLERABILITY AND EFFICACY OF SUBCUTANEOUS PF-06741086 IN SUBJECTS WITH SEVERE HEMOPHILIA

Last checked: Nov 20, 2026Latest source record: Jul 27, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

20

Actual

Start

May 30, 2018

Primary completion

Aug 5, 2020

Study completion Aug 5, 2020

Sponsor

Lead sponsor
PfizerPfizer (PFE)
Sponsor type
Industry
First posted
Dec 6, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Prevention
FDA-regulated drug
Yes
Who can join
Male only, from 12 years, up to 74 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is designed to evaluate the safety, tolerability and efficacy of long-term treatment with PF-06741086 in subjects with severe hemophilia who participated in the 3-month Phase 1b/2 B7841002 study. Additionally, de novo subjects will be recruited into this study.

Conditions

  • Hemophilia A or B

Interventions

  • PF-06741086Biological

    PF-06741086 subcutaneous injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Treatment-Emergent Adverse Events (TEAEs), TEAEs by Severity, and Serious Adverse Events (SAEs) (All Causality and Treatment-Related)Time frame: Day 1 up to Day 393
  2. Number of Participants With Abnormal Laboratory Findings Without Regard to Baseline Abnormality (Including Hematology, Serum Chemistry, and Urinalysis)Time frame: Hematology and serum chemistry: Baseline, Days 1, 29, 57, 85, 169, 253, and 365 visits. Urinalysis: Baseline, Days 1, 85, 169, 253, and 365 visits.
  3. Number of Participants With Changes From Baseline in Vital Signs Measurements Meeting the Pre-Defined Categorical Summarization CriteriaTime frame: Baseline, Days 1, 29, 57, 85, 113, 141, 169, 197, 225, 253, 281, 309, 337, 365 and 393 visits.
  4. Number of Participants With Change From Baseline in Electrocardiogram (ECG) Parameters Meeting the Pre-defined Categorical Summarization CriteriaTime frame: Baseline, Days 1 and 29 visits
  5. Number of Participants With Abnormalities in Physical Examination FindingsTime frame: Day 1 to Day 393
  6. Number of Participants With Injection Site ReactionsTime frame: Day 1 to Day 365, and Day 393 visit.

Locations

8 sites in 7 countries. Site status is shown where the registry gives one.

  • UC Denver Hemophilia and Thrombosis Center

    Aurora, Colorado

  • Centro de Hematologia e Hemoterapia de Campinas- Hemocentro de Campinas

    Campinas, São Paulo, Brazil

  • Hospital Dr. Sotero del Rio

    Santiago, Puente ALTO, Chile

  • Klinicki bolnicki centar Zagreb

    Zagreb, Croatia

  • Klinika Hematologii i Transplantologii Uniwersyteckie Centrum Kliniczne

    Gdansk, Poland

  • Phoenix Pharma (Pty) Ltd

    Port Elizabeth, Eastern Cape, South Africa

  • Charlotte Maxeke Johannesburg Academic Hospital

    Johannesburg, Gauteng, South Africa

  • UniversitatsSpital Zurich

    Zurich, Switzerland

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.